Clinical Trial

PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

Name: PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC — clinical trial record (NCT07645222)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-07

Trial Details

NCT Number	NCT07645222
Lead Sponsor	Hansoh BioMedical R&D Company
Conditions	Lung Cancer
Enrollment	396 participants
Start Date	2026-06-15
Primary Completion	2028-10-31 (estimated)
Study Completion	2029-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-06